ReveraGen, Santhera get FDA grant for BMD trial of vamorolone
ReveraGen Biopharma and Santhera Pharmaceuticals have secured a $1.2 million grant for funding their clinical trial of vamorolone in Becker muscular dystrophy (BMD) from the US Food and Drug Administration (FDA). The orphan grant funding has been issued under Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) grants program. It adds […]